Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development

Abstract

Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53null mice. This has led to the suggestion that absence of p53 alone is not sufficient for induction of mammary tumors. However, early death of p53null mice from thymic lymphomas may obscure tumor phenotypes that would develop later. Therefore, p53null mammary epithelium was transplanted into cleared mammary fat pads of wild type p53 BALB/c hosts to allow long-term analysis of mammary tumor phenotypes. Five treatments were compared for their effects on tumor incidence in hosts bearing transplants of p53null and p53wt mammary epithelium. The treatment groups were: (1) untreated; (2) continuous hormone stimulation with pituitary isografts; (3) multiple pregnancies; (4) DMBA alone; and (5) DMBA+pituitary isografts. The tumor incidences in p53null vs p53wt mammary transplants for each treatment group were 62% vs 0%, 100% vs 0%, 68% vs 0%, 60% vs 4% and 91% vs 14%, respectively. The mammary tumors that developed in the p53null mammary epithelium were all adenocarcinomas and were frequently aneuploid. These data demonstrate that the absence of p53 is sufficient to cause development of mammary tumors and that hormonal stimulation enhances the tumorigenicity of p53null mammary epithelium to a greater extent than DMBA exposure alone. This model provides an in situ approach to examine the molecular basis for the role of p53 in the regulation of mammary tumorigenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Amundadottir LT, Johnson MD, Merlino G, Smith GH and Dickson RB. . 1995 Cell Growth Differ. 6: 737–748.

  • Bouffler SD, Kemp CJ, Balmain A and Cox R. . 1995 Cancer Res. 55: 3883–3889.

  • Cardiff RD and Wellings SR. . 1999 J. Mammary Gland Biol. Neoplasia 4: 105–122.

  • Christov K, Swanson SM, Guzman RC, Thordarson G, Jin E, Talamantes F and Nandi S. . 1993 Carcinogenesis 14: 2019–2025.

  • Coles C, Condie A, Chetty U, Steel CM, Evans HJ and Prosser J. . 1992 Cancer Res. 52: 5291–5298.

  • Delmolino L, Band H and Band V. . 1993 Carcinogenesis 14: 827–832.

  • Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi Y-P, Pinkel D, Gray J, Bradley A, Medina D and Varmus HE. . 1995 Genes Dev. 9: 882–895.

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS and Bradley A. . 1992 Nature 356: 215–221.

  • Elledge RM and Allred DC. . 1994 Breast Cancer Res. Treatment 32: 39–47.

  • Fukasawa K, Choi T, Kuriyama R, Rulong S and Vande WG. . 1996 Science 271: 1744–1747.

  • Fukasawa K, Wiener F, Vande WG and Mai S. . 1997 Oncogene 15: 1295–1302.

  • Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA and Windle JJ. . 1997 Mol. Cell Biol. 17: 723–731.

  • Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT and Weinberg RA. . 1994 Curr. Biol. 4: 1–7.

  • Jerry DJ, Butel JS, Paulson EP, Cochran C, Wiseman RW, Donehower LA and Medina D. . 1994 Mol. Carcinogen. 9: 175–183.

  • Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson ES, Marconi S and Naber SP. . 1998 Oncogene 17: 2305–2312.

  • Kito K, Kihana T, Sugita A, Murao S, Akehi S, Sato M, Tachibana M, Kimura S and Ueda N. . 1996 Mol. Carcinog. 17: 78–83.

  • Kumar R, Medina D and Sukumar S. . 1990 Oncogene 5: 1271–1277.

  • Lehman TA, Modali R, Boukamp P, Stanek J, Bennett WP, Welsch JA, Metcalf RA, Stampfer MR, Fusenig N, Rogan EM and Harris CC. . 1993 Carcinogenesis 14: 833–839.

  • Li B, Murphy KL, Laucirica R, Kittrell F, Medina D and Rosen JM. . 1998 Oncogene 16: 997–1007.

  • Li B, Rosen JM, McMenamin-Balano J, Muller WJ and Perkins AS. . 1997 Mol. Cell. Biol. 17: 3155–3164.

  • Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP and Finlay CA. . 1997 Genes Dev. 11: 714–725.

  • Maroulakou IG, Shibata MA, Jorcyk CL, Chen XX and Green JE. . 1997 Mol. Carcinog. 20: 168–174.

  • McCormack SJ, Weaver Z, Derning S, Natarajan G, Torri J, Johnson MD, Liyanage M, Ried T and Dickson RB. . 1998 Oncogene 16: 2755–2766.

  • McKenzie KE, Armstrong BA, Chen Y, Nagarajan M, Aldaz CM and Sukumar S. . 1997 Mol. Carcinog. 20: 194–203.

  • Medina D. . 1973 Meth. Cancer Res. 7: 3–53.

  • Medina D. . 1974 J. Natl. Cancer Inst. 53: 213–221.

  • Medina D. . (1982) Mammary tumors. In: Foster L, Small JD and Fox JG . (eds). The Mouse in Biomedical Research Academic Press, New York pp. 373–396.

    Google Scholar 

  • Medina D. . 1996 Mam. Gland Biol. Neoplasia 1: 5–19.

  • Medina D and Smith GH. . 1999 J. Natl. Cancer Inst. 91: 967–969.

  • Medina D, Stephens LC, Bonilla PJ, Hollmann A, Schwahn D, Kuperwasser C, Jerry DJ, Butel JS and Meyn RE. . 1998 Mol. Carcinogen. 22: 199–207.

  • Muller WJ, Sinn E, Pattengale PK, Wallace R and Leder P. . 1988 Cell 54: 105–115.

  • Peto R. . 1974 Br. J. Cancer 29: 101–105.

  • Qing WG, Conti CJ, LaBate M, Johnston D, Slaga TJ and MacLeod MC. . 1997 Carcinogenesis 18: 553–559.

  • Ritland SR, Rowse GJ, Chang Y and Gendler SJ. . 1997 Cancer Res. 57: 3520–3525.

  • Ross JA and Nesnow S. . 1999 Mutat. Res. 424: 155–166.

  • Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR and van Zwieten MJ. . 1990 Lab. Invest. 62: 244–278.

  • Sivaraman L, Stephens LC, Markaverich BM, Clark JA, Krnacik S, Conneely OM, O'Malley BW and Medina D. . 1998 Carcinogenesis 19: 1573–1581.

  • Tzeng Y-J, Guhl E, Graessmann M and Graessmann A. . 1993 Oncogene 8: 1965–1971.

  • Tzeng YJ, Zimmermann C, Guhl E, Berg B, Avantaggiati ML and Graessmann A. . 1998 Oncogene 16: 2103–2114.

  • Wellings SR, Jensen HM and Marcum RG. . 1975 J. Natl. Cancer Inst. 55: 231–271.

Download references

Acknowledgements

We would like to acknowledge the technical assistance of Valerie Lutes. This work was supported in part by grants from the Massachusetts Department of Public Health (34088PP1017, DJJ), and the National Institutes of Health (CA66670, DJJ; CA25215, JSB and DM).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jerry, D., Kittrell, F., Kuperwasser, C. et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 19, 1052–1058 (2000). https://doi.org/10.1038/sj.onc.1203270

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203270

Keywords

This article is cited by

Search

Quick links